Kobe, Japan

Itsuo Makino


Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 51(Granted Patents)


Location History:

  • Kobe, JP (1981 - 1983)
  • Hyogo, JP (1984 - 1986)
  • Osaka, JP (2010)

Company Filing History:


Years Active: 1981-2010

Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovator in Pharmaceuticals: Itsuo Makino

Introduction

Itsuo Makino is a renowned inventor based in Kobe, Japan, known for his substantial contributions to pharmaceutical innovations. With a portfolio of nine patents, he has made significant strides in the field of medicinal chemistry, particularly in developing compounds aimed at treating allergic diseases.

Latest Patents

Among his most notable inventions is the patent for an azaindole derivative that possesses PGD2 receptor antagonistic activity. This innovative compound serves as an active ingredient in a pharmaceutical composition designed to treat allergic diseases, marking a significant advancement in therapeutic options. Another key invention is the aminoalkylbenzene derivative, which showcases his ability to create complex chemical structures that have potential medicinal uses.

Career Highlights

Itsuo Makino has held influential roles at prominent organizations such as Shionogi & Company Limited and Teikoku Hormone Manufacturing Co., Ltd. His work at these firms has allowed him to leverage his expertise in drug development, contributing to the advancement of pharmaceutical sciences.

Collaborations

Throughout his career, Makino has collaborated with esteemed colleagues, including Kentaro Hirai and Teruyuki Ishiba. These partnerships have fostered a collaborative environment that promotes innovation and breakthroughs in their respective fields.

Conclusion

Itsuo Makino's contributions to medicinal chemistry and pharmaceutical innovations highlight his importance as an inventor. His body of work not only enriches the scientific community but also provides valuable therapeutic options for individuals suffering from allergic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…